Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
about
Translational Bioinformatics: Past, Present, and FutureCracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and PerspectivesMolecular Technologies in the Clinical Diagnostic LaboratoryThe possibility of clinical sequencing in the management of cancerSpontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapyNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Development and validation of the JAX Cancer Treatment Profileā¢ for detection of clinically actionable mutations in solid tumors.Targeted Next-Generation Sequencing for Clinical Diagnosis of 561 Mendelian Diseases.Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Effective quality management practices in routine clinical next-generation sequencing.Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded MaterialValidation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsImplementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancerMolecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.Toward clinical genomics in everyday medicine: perspectives and recommendationsIdentification of a Novel Pathogenic Germline KDR Variant in Melanoma.Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assayPragmatic precision oncology: the secondary uses of clinical tumor molecular profilingDetermination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.Institutional implementation of clinical tumor profiling on an unselected cancer population.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencingComprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing.The rise of genomic profiling in ovarian cancer.Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.A Next-Generation Sequencing Primer-How Does It Work and What Can It Do?The impact of pharmacokinetic gene profiles across human cancers.Precision oncology: separating the wheat from the chaff
P2860
Q26766146-02D5BDA0-C6FA-4D8D-8315-33AC90D65ECAQ26776038-21E55B3C-2A7A-4455-9E75-7043517E22F7Q26996463-9C94154C-2C11-4004-B6B6-EC8DFD4498E4Q28072144-B7F96C25-CC45-4965-B18E-16397CCDE3EFQ34097654-7E525B64-1353-4A41-91A8-F2E919CAEEADQ34550417-A8F3DDA7-FCAA-42E6-B039-751D900B5BFCQ35538750-8E99DC1A-4F0B-455D-8DBD-92F10D8E4C39Q35746050-42358EAC-4036-45BF-936A-9FEAD0007630Q35749307-56531217-E6E4-46CA-9D5F-3D513E75AD73Q35922622-4AADA7BE-5741-41DB-AF22-C1C8F585D342Q35937517-F36365A0-F1A8-405D-9731-E6DE98435F85Q35996102-C51C1607-DA9F-40AC-BE70-AE300FCA2C3BQ35998823-63A87DBF-C7E3-4FD8-A70F-F5C520CCD10CQ36064946-9BF74C36-E6AE-4DD2-AEE6-BFC77B4EDFB0Q36188758-22FC381F-7D40-4741-93D7-92D89186EBA1Q36544915-6FD860A5-FB1A-4906-8595-C6A40428EBB3Q36825747-CFCE1E68-DF15-47E4-AEF5-5AFE7E959AE0Q36902033-77EDAD96-770B-4A32-9777-2E423B4D7277Q36962764-592FB459-76DF-4518-8478-5123E8312D8EQ37051413-E989F8CE-591C-4FE5-A78A-458310FD96DFQ37225594-9FD9F866-C775-4E02-81CE-920946343CD6Q37417570-14B1EEC8-8C11-4326-8B47-5DB5520CEA21Q37648114-A5F14D2E-9F24-46C5-B64E-918E958E576FQ38364614-5A496B41-1582-4B3F-8323-F8DB2F527601Q38387634-FBC4BF15-C6E6-4B6F-B15F-AF035B18A1B8Q38759643-012252CB-C849-4FD4-9A24-42E72D03F0D7Q41041680-3A444616-2B73-4024-9A09-D6C44EA0B1A5Q41571663-8FDA497B-AACA-4EFB-86D4-4CFBDB4E56C1Q45977883-75E9750E-A99E-4625-8016-27968FE79CE0Q46529281-C6DBA23D-A9ED-474E-A898-F1DF83816B2CQ48519733-CBD43CB1-F1B3-4826-BC1A-A0A6F11B5350Q50239136-6DEB87A2-73A7-4215-8DF6-326D0BDCBA06Q50345037-7D16E5AC-5844-49E6-8452-E42204210D59Q53117505-72FD9D9F-931C-48BA-9BF9-E69D069347E4Q54996932-A786E301-4D52-4109-9545-BC343B0F3806Q55294975-AF0AD41F-2AAE-46D9-85CC-4FEFEF5E1FA0Q58698377-654E4C8A-55F0-44FB-A29E-D7E5437CA84E
P2860
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
description
2014 nĆ® lÅ«n-bĆ»n
@nan
2014 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2014 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ“Õ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2014幓ć®č«ę
@ja
2014幓č«ę
@yue
2014幓č«ę
@zh-hant
2014幓č«ę
@zh-hk
2014幓č«ę
@zh-mo
2014幓č«ę
@zh-tw
2014幓č®ŗę
@wuu
name
Enabling a genetically informe ...... xt-generation sequencing panel
@ast
Enabling a genetically informe ...... xt-generation sequencing panel
@en
type
label
Enabling a genetically informe ...... xt-generation sequencing panel
@ast
Enabling a genetically informe ...... xt-generation sequencing panel
@en
prefLabel
Enabling a genetically informe ...... xt-generation sequencing panel
@ast
Enabling a genetically informe ...... xt-generation sequencing panel
@en
P2093
P2860
P50
P1433
P1476
Enabling a genetically informe ...... xt-generation sequencing panel
@en
P2093
Barbara A Murphy
Carlos L Arteaga
Douglas B Johnson
Igor Puzanov
Ingrid A Mayer
Jared Knol
Jeffrey A Sosman
Jill Gilbert
Jordan D Berlin
Julie Means-Powell
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0011
P577
2014-05-05T00:00:00Z